<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02038621</url>
  </required_header>
  <id_info>
    <org_study_id>2ndSichuan</org_study_id>
    <secondary_id>GZH-001</secondary_id>
    <nct_id>NCT02038621</nct_id>
  </id_info>
  <brief_title>The Maintenance Therapy of Capecitabine of Advanced Gastric Cancer</brief_title>
  <acronym>GZH-001</acronym>
  <official_title>Phase II Clinical Study of the Maintenance Therapy of Capecitabine Afer the XELOX in Treatment of Advanced Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Second People's Hospital of Sichuan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Second People's Hospital of Sichuan</source>
  <brief_summary>
    <textblock>
      To confirm the efficacy and safety of XELOX with capecitabine maintenance in treatment of
      advanced gastric cancer (AGC)
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival (OS)</measure>
    <time_frame>from the date of randomization until death from any cause or up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events (AE)</measure>
    <time_frame>from date of randomization to 28 days after the last chemo dosage</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>health-related quality of life (HRQOL</measure>
    <time_frame>evaluate every 6 weeks from the date of randomization until 28 days after the last chemo dosage</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">224</enrollment>
  <condition>Advanced Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Capecitabine: 1000mg/m^2 bid, days 1-14, every 3 weeks until progression/intolerance.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Observation until progression</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin and Capecitabine</intervention_name>
    <description>Before randomization,all enrolled patients underwent 3 cycles XELOX chemotheray. After patients' disease achieved CR\PR\SD,then randomized into this clinical trial.</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years old

          -  male or female

          -  Patients with stage IV gastric cancer by pathology or cytology and imaging diagnosis ,
             or after previous surgery or radiotherapy or chemotherapy in patients with stage IV
             gastric cancer progression , there RECIST criteria evaluable lesions ;

          -  ECOG performance status score 0-2 ;

          -  Expected survival time more than three months ;

          -  Adequate hematologic parameters and liver and kidney function ;

          -  Bone marrow : absolute neutrophil count (ANC) ≥ 1.5 × 109 / L, platelets ≥ 75 × 109 /
             L, hemoglobin ≥ 80g / L;

          -  Liver: bilirubin ≤ 1.5 times the upper limit of normal , ALT AST values ≤ 2.5 times
             the upper limit of normal ;

          -  Renal : serum creatinine ≤ ULN ;

          -  Informed consent of patients or their agents , and signed informed consent.

        Exclusion Criteria:

          -  For patients allergic to capecitabine ;

          -  Patients with CNS metastases

          -  Undermine the integrity of the upper gastrointestinal tract , malabsorption syndrome ,
             or unable to take oral medication ;

          -  Patients with coronary heart disease , angina , myocardial infarction , arrhythmia,
             cerebral thrombosis, stroke and other serious cardiovascular and cerebrovascular
             disease ;

          -  Or in combination with other anti-tumor therapy in patients participating in clinical
             trials of other interventions ;

          -  Pregnancy or breast-feeding patients , or fertility without taking adequate
             contraceptive measures were ;

          -  The researchers believe that this test is not suitable for those who participate .
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Chengya Zhou, bachelor</last_name>
    <phone>86 13980972569</phone>
    <email>yaya713913@126.com</email>
  </overall_contact>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2014</study_first_submitted>
  <study_first_submitted_qc>January 15, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2014</study_first_posted>
  <last_update_submitted>January 15, 2014</last_update_submitted>
  <last_update_submitted_qc>January 15, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Second People's Hospital of Sichuan</investigator_affiliation>
    <investigator_full_name>Chengya Chou</investigator_full_name>
    <investigator_title>Oncology physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

